Genezen, a gene therapy CDMO, has agreed to acquire uniQure’s commercial gene therapy operations in Lexington, MA, bringing a strategic manufacturing facility and an experienced team of employees to the company.

Under the terms of the agreement, Genezen will enter into strategic supply agreements for uniQure’s clinical portfolio and CSL’s commercial HEMGENIX product, the first one-time gene therapy approved in the U.S. and Europe for the treatment of adults with severe and moderately severe Hemophilia B.

Located just outside of Boston, the Lexington site is a commercially-licensed viral vector facility, enabling Genezen to support customers from preclinical development programs through late-phase and commercial manufacturing. The facility also includes a laboratory space and pilot plant that will serve as Genezen’s global AAV center of excellence. The Lexington site will complement Genezen’s existing clinical manufacturing operations and team in Indianapolis, IN.

Steve Favaloro, President and CEO of Genezen, commented, “I am thrilled to welcome the Lexington team and the addition of a state-of-the-art, licensed viral vector manufacturing facility to Genezen. This acquisition significantly enhances Genezen’s scale and differentiated capabilities, directly aligned with our mission to advance cell and gene therapies by providing top-tier, science-driven development and manufacturing solutions. We are honored to deliver these services to our current customers and the patients they serve, and are well positioned to immediately extend our support to even more customers in Lexington.”

“uniQure has been a pioneer in gene therapy manufacturing for the past 15 years, and we are pleased to have found a partner in Genezen to take the facility and team into its next phase of growth,” stated Matt Kapusta, CEO of uniQure. “This transaction provides us with continued access to the world-class manufacturing capabilities we established and the talented, dedicated people who support the facility every day. We look forward to beginning our collaboration with Genezen and are committed to ensuring a seamless transition.”

Mike Deem, Head of CSL Behring Operations, said, “We are excited to expand our relationship with Genezen and have them take on HEMGENIX commercial supply from the Lexington manufacturing operation, continuing to optimize the manufacturing process and help us ensure a reliable supply for patients.”

This transaction will be funded in part by additional growth equity from Ampersand Capital Partners.